Tumor Marker Antigens for Immunoassays: CEA, AFP, CA125 and CA19-9

Updated 2026-09-28

Selecting antigen material for CEA, AFP, CA125 and CA19-9 immunoassays: what differs between these tumor markers at the bench.

Four Markers, Four Biochemistries

CEA, AFP, CA125 and CA19-9 are widely used tumor markers, but they are chemically distinct. CEA is a glycoprotein of the immunoglobulin superfamily; AFP is a fetal plasma protein; CA125 (MUC16) is a large mucin; and CA19-9 is a carbohydrate antigen, a sialylated Lewis structure carried on glycolipids and glycoproteins. Treating these analytes as interchangeable protein markers is a common early mistake. Because they differ in nature, no single assay strategy suits all four. Antigen choice and antibody design must follow the biochemistry of each analyte, and the calibrator must present the epitope the antibody recognises.

Antigen Source and Heterogeneity

For protein markers such as CEA and AFP, recombinant or purified native material can be used, and the choice affects which epitopes are present. Glycosylation varies with the expression system, and some antibodies recognise carbohydrate-dependent epitopes while others do not. For a carbohydrate antigen such as CA19-9, the analyte is not a single protein, so calibrator material must present the correct epitope in a defined form. Establish which epitope your antibody recognises before committing to a calibrator.

Standardisation and Calibrators

Tumor marker assays have historically been difficult to harmonise, because different methods measure different forms and report different numerical results for the same sample. Calibrators should be traceable and their composition documented, including the form of the antigen and the matrix. Gold and Freedman described CEA in the Journal of Experimental Medicine (1965); Bast and colleagues reported the CA125 assay in the New England Journal of Medicine (1983); and Magnani and colleagues characterised the CA19-9 epitope in Science (1981).

Antigen heterogeneity and what it does to your calibrator

Tumor marker analytes are heterogeneous to a degree that most immunoassay developers underestimate at first, and the heterogeneity sits between the antibody and the calibrator. Carcinoembryonic antigen exists in multiple forms differing in glycosylation and in the degree of membrane association, and the choice of expression system determines which of those forms a recombinant preparation resembles. Alpha-fetoprotein shows microheterogeneity in its carbohydrate chains, and antibodies differ in whether they read the protein or the carbohydrate. CA125 is a large mucin whose measurement is strongly influenced by which epitopes are exposed and by the presence of the cleaved circulating form. The practical consequence is that a calibrator is valid only against the specific antibody pair it was qualified with, and a change of either reagent invalidates the qualification even when the analyte name on the vial is identical.

Sourcing notes for four markers that behave differently

The first antigen of this group to be characterised was carcinoembryonic antigen, identified in colonic tissue in the mid-1960s, and the marker's long history is a reminder that assays for it have been built and rebuilt across several generations of technology. Alpha-fetoprotein entered use through prenatal screening and hepatocellular carcinoma monitoring, where the reference intervals differ by population and by purpose. The CA125 radioimmunoassay was reported in the early 1980s and remains the archetype of a mucin-based tumor marker, with all the calibrator difficulties that implies. CA19-9 is not a protein at all: the epitope is a sialylated Lewis carbohydrate structure, which means the calibrator must present that structure in a defined chemical form, and it means antibody specificity has to be established against the carbohydrate rather than against a protein sequence. Treating these four as one purchasing category, as catalogue pages often do, hides the only distinction that matters at the bench.

Ask a technical question